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Abstract
Currently, there is no consensus among the transplant community about the
treatment of renal cell carcinoma (RCC) of the transplanted kidney. Until
recently, graftectomy was universally considered the golden standard, regardless
of the characteristics of the neoplasm. Due to the encouraging results observed in
native kidneys, conservative options such as nephron-sparing surgery (NSS)
(enucleation and partial nephrectomy) and ablative therapy (radiofrequency
ablation, cryoablation, microwave ablation, high-intensity focused ultrasound,
and irreversible electroporation) have been progressively used in carefully
selected recipients with early-stage allograft RCC. Available reports show
excellent patient survival, optimal oncological outcome, and preserved renal
function with acceptable complication rates. Nevertheless, the rarity and the
heterogeneity of the disease, the number of options available, and the lack of
long-term follow-up data do not allow to adequately define treatment-specific
advantages and limitations. The role of active surveillance and
immunosuppression management remain also debated. In order to offer a better
insight into this difficult topic and to help clinicians choose the best therapy for
their patients, we performed and extensive review of the literature. We focused
on epidemiology, clinical presentation, diagnostic work up, staging strategies,
tumour characteristics, treatment modalities, and follow-up protocols. Our
research confirms that both NSS and focal ablation represent a valuable
alternative to graftectomy for kidney transplant recipients with American Joint
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Core tip: Nephron-sparing surgery and ablative therapy have been increasingly
recognised as a valuable alternative to transplantectomy in carefully selected kidney
recipients with allograft renal cell carcinoma (RCC). The complexity of the disease, the
numerosity of the treatments available, the lack of long-term follow-up data, and the
relatively poor quality of the studies addressing this topic do not allow to properly define
specific advantages and limitations of these conservative strategies. We performed an
extensive review of the literature focusing on epidemiology, clinical presentation,
diagnostic work up, staging strategies, tumour characteristics, treatment modalities, and
follow-up protocols of localised RCC of the transplanted kidney.
Citation: Motta G, Ferraresso M, Lamperti L, Di Paolo D, Raison N, Perego M, Favi E.
Treatment options for localised renal cell carcinoma of the transplanted kidney. World J
Transplant 2020; 10(6): 147-161
URL: https://www.wjgnet.com/2220-3230/full/v10/i6/147.htm
DOI: https://dx.doi.org/10.5500/wjt.v10.i6.147
INTRODUCTION
Kidney transplant (KTx) recipients have a survival advantage compared to patients
on chronic dialysis or remaining on the transplant waiting list (TWL)[1,2]. Nevertheless,
due  to  the  synergistic  effect  of  end-stage  renal  disease  (ESRD)  and  prolonged
exposure to powerful immunosuppressive agents, higher incidences of malignancies
and  inferior  cancer-specific  survivals  than  the  general  population  have  been
reported[3-6].  Among neoplastic  complications,  renal  cell  carcinoma (RCC) of  the
transplanted  kidney  has  been  increasingly  recognised  as  an  important  cause  of
morbidity  and  premature  allograft  loss[7-9].  Management  can  be  exceptionally
challenging because in  this  complex subset  of  patients  the  theoretical  benefit  of
optimal oncological control must be carefully weighed against the substantial risk of
death  arising  from  technically  demanding  surgical  procedures,  peri-operative
complications, and return to dialysis[8,10].
For many years,  transplantectomy has been universally considered the golden
standard, regardless of the characteristics of the lesion[11]. More recently, widespread
and successful application of nephron-sparing surgery (NSS) and ablative therapy
(AT) for the treatment of solid neoplasms in native kidneys[12] has favoured the use of
conservative approaches in renal allografts[13]. Enucleation, partial nephrectomy (PN),
radiofrequency ablation (RFA),  cryoablation,  microwave ablation (MWA),  high-
intensity focused ultrasound (HIFU), and irreversible electroporation (IRE) have been
proposed as valuable alternatives to graftectomy in carefully selected recipients with
localised RCC but evidence remain weak[13,14]. The rarity of the disease, the numerosity
of  the  techniques,  and  the  quality  of  the  studies  (mostly  case  reports  or  small
retrospective  case  series)  do  not  allow  to  adequately  assess  treatment-specific
outcomes and to  clearly  define indications and limitations[13,14].  In  particular,  no
clinical guidelines or comprehensive meta-analyses have been published and there is
still concern in the transplant community regarding long-term efficacy and safety. In
order to offer a better insight into this difficult topic and to help clinicians choose the
best therapy for their patients, we performed and extensive review of the literature
focusing on conservative treatments of localised RCC.
LITERATURE RESEARCH
PubMed was searched for manuscripts reporting on RCC of the transplanted kidney.
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No time limits  were applied.  The following key words combinations were used:
“kidney transplant  neoplasm”,  “kidney transplant  tumour”,  “kidney transplant
mass“, “kidney transplant cancer”, “kidney transplant renal cell carcinoma”, “renal
transplant neoplasm”, “renal transplant tumour”, “renal transplant mass“, “renal
transplant  cancer”,  “renal  transplant  renal  cell  carcinoma”,  “kidney  allograft
neoplasm”, “kidney allograft tumour”, “kidney allograft mass“, “kidney allograft
cancer”, “kidney allograft renal cell carcinoma”, “renal allograft neoplasm”, “renal
allograft tumour”, “renal allograft mass“, “renal allograft cancer”, “renal allograft
renal cell carcinoma”, “nephrectomy”, “transplantectomy”, “graftectomy”, “nephron-
sparing surgery”, “ablation”, “radiofrequency ablation”, “cryoablation”, “microwave
ablation”,  “high-intensity  focused  ultrasound”,  “irreversible  electroporation”,
“surveillance”, and “watchful waiting”. Preliminary screening was performed by
Motta G, Ferraresso M, Lamperti L, Di Paolo D, and Favi E. Manuscripts reporting on
localised kidney allograft RCC were further evaluated by Motta G and Favi E as a
potential  source  of  information  for  the  review.  Considered  sub-topics  were:
Epidemiology, clinical presentation, diagnosis, staging, neoplasms’ characteristics,
treatment options, and follow-up strategies.
EPIDEMIOLOGY
Reported incidence of primary RCC in kidney allografts varies between 0.2% and
0.5%, depending on the series[7,15-18]. However, taking into account the progressive
aging of the patients on the TWL[19],  the increased utilization of expanded-criteria
donors[20],  and the significant amelioration of long-term recipient survival[2],  it  is
reasonable  to  expect  that  the  cumulative  incidence  of  the  disease  will  rise
considerably in the next few years. KTx patients are approximately at 2-fold increased
risk of developing malignancies than healthy controls[21]. Compared to the general
population, the risk of developing RCC is 10-fold higher[22].  Even though, several
studies have demonstrated an association between specific primary renal diseases,
ESRD, long-term dialysis, immunosuppressive therapy and post-transplant RCC, the
reason behind this increased susceptibility remains unknown[13,17,18,23,24].
Higher incidences of allograft RCC have been shown among patients receiving a
kidney from a deceased donor compared to living donor recipients[7,13,14]. As pointed
out by Griffith et al[7], this trend probably mirrors the disparity between the number of
deceased and living donor transplants performed in most countries. Age differences
and disparities in cancer screening protocols between donor types may also play a
role[14,25]. Other possible variables such as deceased donor category, ethnicity, gender
or age have not been extensively investigated. Regarding recipient’s characteristics, a
disproportion of male patients with RCC of the transplanted kidney was observed by
Tillou et al[13].
Allograft RCC are predominantly of donor origin[25]. However, lesions arising from
recipient-derived cells have been reported[26]. Albeit generally neglected by current
diagnostic and staging protocols, discriminating between transmitted and acquired
allograft neoplasms might have relevant therapeutic and prognostic consequences
that should encourage further investigation.
CLINICAL PRESENTATION
Overall,  no  more  than 20% of  the  patients  exhibit  clinical  manifestations  of  the
disease[7]. The vast majority of lesions are asymptomatic and incidentally discovered
during imaging studies performed as a part of the routine post-transplant follow-up
or  to  rule  out  other  conditions [7 ,13 ,14 ,18 ,27 ].  According  to  the  largest  studies
available[7,13,14,18],  most  frequently  reported  symptoms  eventually  leading  to  the
diagnosis of allograft RCC are haematuria, abdominal pain, asthenia, weight loss,
fever, flu-like syndrome, hypertension, recurrent urinary tract infections, and allograft
dysfunction.
DIAGNOSIS
Localised allograft  RCC often represents  an incidental  finding[27].  Reported time
intervals between transplantation and diagnosis are extremely variable[9,14,15,28]. Colour-
Doppler  ultrasound  (US)  is  widely  considered  the  first  line  modality  for  the
evaluation of solid masses of the transplant[16,27,29]. In case of indeterminate lesions,
contrast-enhanced computed tomography (CT) scan and magnetic resonance imaging
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(MRI) with or without contrast dye are the preferred options[14,18].  More recently,
excellent results have been demonstrated using contrast-enhanced US (CEUS)[30]. Main
advantages of CEUS over contrast-enhanced CT scan and MRI are lack of radiation
exposure, avoidance of contrast-induced nephropathy (CIN) or nephrogenic systemic
sclerosis,  and  cost  savings[31].  In  order  to  avoid  diagnostic  delays  that  may
compromise the chance of conservative treatment or unnecessary interventions that
may irreversibly damage the transplanted kidney,  an allograft  biopsy should be
obtained whenever possible[7,14,18]. Histology not only allows to assess type, grading,
and  origin  of  the  neoplasm  but  also  provides  fundamental  information  for
epidemiological and clinical purposes.
STAGING
Since accepted indication for conservative treatment of allograft RCC is restricted to
localised neoplasms, careful staging is mandatory. The staging system proposed by
the  American  Joint  Committee  on  Cancer  (AJCC)  for  RCC  in  native  kidneys  is
currently the most used tool in combination with the Fuhrman grading score[32,33].
However, the transplanted kidney has peculiar anatomical characteristics that may
limit the use of standard staging tools. In this regard, the modified version of the
AJCC staging system proposed by the Comité de Transplantation de l’Association
Française d’Urologie seems a better option[18]. According to Tillou et al[18], T3 tumours
extend into major veins or invade renal sinus fat or peritoneum whereas T4 lesions
invade perinephric organs such as psoas muscle, iliac vessels wall, bladder, small
intestine or colon. There is no consensus among the transplant community on the
optimal staging work up. Contrast-enhanced abdomen CT scan and MRI with or
without contrast material are the preferred imaging techniques in most centres[7,14,18,34].
Albeit recommended by the American Urology Association (AUA) guidelines[32] and
the European Association of Urology (EAU) guidelines[33], contrast-enhanced chest CT
scan is seldom included in KTx RCC staging protocols.
CANCER CHARACTERISTICS
Similarly to native kidneys, three main variants of RCC have been identified in renal
allografts:  Clear cell,  papillary, and chromophobe[7,14,18].  Compared to the general
population, a significantly higher prevalence of papillary type over clear cell type has
been observed among KTx patients[7,14,18]. The reason behind this difference is obscure.
Even though, papillary RCC is generally less aggressive than clear cell RCC, its multi-
focality  has  been  often  considered  a  relative  contraindication  to  conservative
treatments[18,35-37]. More recently, results achieved with AT[14] have demonstrated that
patients with papillary type RCC can be excellent candidate for allograft preservation
strategies.  Another interesting data is  the high proportion of  endophytic  lesions
successfully treated with AT[14]. Endophytic masses have been generally considered
less suitable for AT than exophytic ones. The outcomes reported in renal allografts
seem to contradict this opinion and suggest that tumour growth pattern may not be a
relevant prognostic factor of primary treatment failure. According to the literature,
the vast majority of localised allograft RCC successfully treated with NNS or AT is
less than 4 cm in maximal diameter, Fuhrman grade 1-2, and staged T1aN0M0[14,18,34].
Conservative management of T1bN0M0 RCC remains anecdotal and seems to offer
mixed outcomes[14,38-41].
TREATMENT OPTIONS AND TREATMENT-SPECIFIC
OUTCOMES
Graftectomy
For many years, graftectomy has represented the only acceptable option for RCC of
the transplanted kidney[14,42]. However, death rates as high as 3% with up to 50% of the
patients  experiencing  severe  post-operative  complications  have  been  reported
following this aggressive surgical procedure[43]. Studies comparing NNS and AT to
graftectomy, especially in recipients with T1aN0M0 lesions, have shown comparable
oncological  outcomes  with  fewer  complications [ 7 , 1 4 , 4 2 ] .  For  these  reasons,
transplantectomy should be currently restricted to patients with irreversible allograft
dysfunction, sarcomatoid type RCC, multi-focal papillary type RCC, RCC greater than
7 cm in maximal diameter (AJCC stage II), locally-invasive or metastatic RCC (AJCC
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stage III  or IV),  and RCC infiltrating critical  structures.  Recent data support this
position and demonstrate that for T1aN0M0 RCC a 5-year survival rate of 95% can be
expected[9,44] whereas 5-year survival rate after allograft removal and return to dialysis
is only 34%[8]. Analyses of non-cancer specific mortality after KTx failure also confirm
the long-term survival benefit of maintained renal function[45,46].
NSS
NSS techniques such as enucleation, wedge resection, and PN are now considered the
treatment of choice for patients with T1aN0M0 RCC in native kidneys[32,33].  Albeit
encouraging, experience in recipients with allograft RCC is limited[7,9,11,39,42,47]. Available
studies demonstrate that with NSS excellent oncological outcomes can be obtained in
patients with T1aN0M0 lesions. Local recurrence rates of less than 5%, lower post-
operative  complication  rates  (between  15%  and  21%,  depending  on  the  series),
marginal impact on allograft function, and the possibility to treat residual or relapsing
neoplasms with further conservative strategies support NSS over transplantectomy.
Successful resection of localised RCC greater than 4 cm in maximal diameter remains
anecdotal and therefore should not favour the use of NSS over graftectomy[39,41]. Main
limitations of NSS compared to AT are invasiveness, higher technical difficulty, and
increased risk of peri-operative complications[7,14,18]. Most cases of NSS in transplant
setting  have  been  performed  using  an  open  technique  but  minimally  invasive
approaches have been also described[39,41]. The tumour can be resected getting access to
the allograft via a retro- or an intra-peritoneal route depending on the location of the
mass[39]. In case of lesions very close to the vessels, renal pedicle control is advised[39].
RFA
RFA is the preferred AT for KTx neoplasms (approximately, 80% of all the procedures
reported in the literature)[14,48]. Excellent oncological and functional outcomes in the
treatment  of  solid  masses  in  native  kidneys  have  undoubtedly  favoured  its
application  in  the  transplant  setting[49-52].  RFA  uses  high-frequency  alternating
electrical current to force extra- and intra-cellular ions to follow the same route as the
current  thus  generating  agitation,  frictional  heat,  and  coagulative  necrosis[53].
Relatively wide thermal dispersion and subsequent risk of thermal damage to critical
peri-lesional structures represent the main limitations of the technique[53]. RFA has
been mostly utilized to treat small exophytic lesions distant from the renal hilum[49,53].
However, experience in allograft RCC demonstrates that it can be effectively used for
both exophytic and endophytic masses[14]. According to a recent systematic review[14],
among 78 T1aN0M0 RCC treated with percutaneous US- or CT-guided RFA, only two
episodes of primary treatment failure and one episode of local recurrence could be
identified. Moreover, persistent and relapsing tumours were successfully managed by
repeated ablation. Safety profile was also encouraging as no peri-operative deaths
were recorded and complication rates did not exceed 15%. The most relevant adverse
events were transient lower limb pain due to thermal injury to nerves or muscles and
urinary leakage secondary to thermal damage to the renal pelvis.  Renal function
preservation was obtained in the vast majority of patients included in the analysis.
Cryoablation
Cryoablation uses a cryogenic freezing unit connected with special hollow needles to
deliver a cooled fluid into the target-tissue and to simultaneously remove heat from it.
At  a  cellular  level,  such a  technique promotes ice  crystal  formation,  irreversible
membrane damage,  cell  lysis,  and apoptosis  whereas at  a  supra-cellular  level,  it
causes ischemic necrosis secondary to intra-vascular coagulation[53]. Compared to RFA
and MWA, cryoablation entails  a  lower  risk  of  thermal  damage to  surrounding
structures. For this reason, it is widely considered the most selective AT and it is
particularly  indicated  for  centrally  located  lesions[53].  Minimal  impact  on  renal
function represents  another important  feature[54].  Possible  limitations,  at  least  as
shown in native kidneys, are higher risk of intra-operative bleeding[55], higher rate of
primary  treatment  failure  in  case  of  neoplasms  greater  than  3  cm  in  maximal
diameter[56-58],  and higher recurrence rate for tumours with an endophytic growth
pattern[59]. To date, only 10 cases of biopsy-proven T1aN0M0 and 1 case of biopsy-
proven T1bN0M0 RCC of the transplanted kidney treated by cryoablation have been
documented[34,60-63]. The procedures were mostly performed percutaneously under US-
or CT-guidance with no persisting disease, no local relapse (post-ablation follow-up
ranging from 1 to 59 mo),  and excellent allograft  function.  Overall,  there were 2
episodes of peri-operative bleeding[14].
MWA
MWA is a thermal ablation modality that uses microwaves to cause oscillation of
polar molecules into the target-lesion thus generating frictional heat and coagulative
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necrosis[53]. Major advantages compared to other AT are the ability to deliver higher
intra-lesion  temperatures,  a  marginal  dependency  on  tissue-specific  electrical
conductivity, simultaneous treatment of multiple neoplasms, and the possibility to
ablate the puncture tract[53,64-66]. There are several studies supporting the application of
MWA for malignant tumours in native kidneys[67,68] but experience in renal allografts
is limited to a couple of small case series. Successful ablation of one Fuhrman grade 1-
2, T1aN0M0 clear cell RCC and two Fuhrman grade 1-2, T1aN0M0 papillary RCC was
first reported by Gul et al[63]. The procedures were performed under CT-guidance via a
percutaneous or a trans-osseous approach with no serious complications, no allograft
dysfunction, and no recurrence after a follow-up ranging from 8 to 61 mo. Other two
cases of MWA of RCC of the transplanted kidney were more recently described by
our group[69]. More in details, we treated one Fuhrman grade 2, T1aN0M0 papillary
RCC and one Fuhrman grade 1, T1aN0M0 clear cell RCC. Ablations were carried out
under US-guidance using an open retro-peritoneal route for the first patient and a
percutaneous approach for the other one. Complete tumour destruction was achieved
in both the operations without complications, loss of allograft function or recurrence
after 3 and 5 years of follow-up, respectively.
HIFU
HIFU incorporates multiple US beams directed into a three-dimensional focal point to
produce tissue destruction by combined effects of thermal and mechanical energies
(more  precisely,  cavitation,  micro-streaming,  and  radiation  forces)[70].  Potential
benefits  of  HIFU  are  fast  action,  minimal  thermal  dispersion,  and  reduced
invasiveness as it does not require direct contact with the target-lesion[71,72]. On the
contrary, recognised limitations of the technique are the need for an optimal acoustic
window, the inability to reach deep organs or tissues due to US penetrance, and
complex pre-operative planning[71,72]. Excellent results have been reported in native
kidneys[73-75] but in KTx setting data are scarce. Searching the literature, we could find
only three cases of allograft RCC treated by HIFU. US-guided percutaneous ablation
of two T1aN0M0 papillary RCC was described by Di Candio et al[76] with excellent
short-term oncological outcomes (6-mo follow-up) and no peri-operative adverse
events whereas multiple unsuccessful attempts in a patient with a 55 mm T1bN0M0
clear cell RCC were reported by Chakera et al[77].
IRE
IRE is a non-thermal AT with extraordinary connective tissue-sparing properties that
has been successfully used to treat renal[78] and extra-renal neoplasms[79]. This novel
treatment modality utilizes an electrical field to generate nanopores into target-cells
and induce  permanent  membrane  permeability,  disruption  of  homeostasis,  and
apoptosis[80,81].  It  is  particularly  indicated  in  case  of  neoplastic  lesions  close  to
important vessels or structures. There is only one study describing the use of IRE in
KTx tumours[63]. The procedure was performed percutaneously under CT-guidance to
ablate a Fuhrman grade 3, T1aN0M0 clear cell RCC. The post-operative course was
uneventful  with  preserved allograft  function and no recurrence  after  3  years  of
follow-up.
Active surveillance
There are no reports describing active surveillance (AS) in KTx recipients with RCC of
the allograft. A major concern is that chronic immunosuppression may increase the
risk  of  cancer  spreading compared to  the  general  population.  Actually,  such an
assumption has never been confirmed. Recent studies have shown that growth rate
and metastatic potential of transplant neoplasms are overall similar to those observed
in native kidneys and in healthy controls[7,9,13,14,18,34]. As such, no hard recommendations
can be made against the use of AS in the transplant setting. A reasonable approach
would be to follow the principles stated by the AUA guidelines[32] and to consider
both patient-related and tumour-related characteristics. As pointed out by Griffith et
al[7], given the higher incidence of papillary RCC observed in recipients with allograft
neoplasms[14,18,82], a lower threshold for renal mass biopsy is advised.
Immunosuppression modification
Immunosuppression  is  a  well-recognised  risk  factor  for  the  development  of
malignancies, particularly infectious-related ones and non-melanoma skin cancers
(NMSC)[83]. Increased susceptibility to long-lasting viral infections with oncogenic
potential and partial loss of immune-surveillance processes are considered the main
reasons  behind  this  phenomenon [ 2 1 , 8 4 , 8 5 ] .  Associations  between  specific
immunosuppressive drugs and risk of cancer after solid organ transplantation have
been extensively investigated. Considering the role of NK[86],  CD4+, and CD8+ T
cells[87] in virus-specific immunity and in eliminating neoplastic cells, lymphocyte-
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depleting  agents  such  as  anti-thymocyte  polyclonal  antibodies[88]  or  anti-CD52
monoclonal antibody alemtuzumab[83,89] and calcineurin inhibitors (CNI) cyclosporine
and tacrolimus[90] seem to play a major role. In particular, CNI have been shown to
exert their action through indirect inhibition of T cells activation/proliferation (via
decreased IL-2 production) and direct up-regulation of VEGF and TGF-b1[91,92].  A
significant link between chronic azathioprine exposure and squamous cell carcinoma
of  the  skin  has  been  also  demonstrated [93].  An  accepted  explanation  is  that
azathioprine inhibits T cells proliferation and alters DNA repair mechanisms thus
leading to impaired immune-surveillance and cell transformation. Data on cancer-
related side effects  of  mycophenolic  acid (MPA)[83,94,95]  and results  of  the  studies
addressing the role of steroids in cancer development[83,87] remain unclear. There is
mounting evidence that proliferation signal inhibitors (PSI)/mammalian target of
rapamycin inhibitors (mTOR-I) sirolimus and everolimus may have important anti-
neoplastic properties[83]. Main immunosuppressive action of mTOR-I is inhibition of T
cells activation/proliferation through down-regulation of IL-2 and cell-cycle block.
Nevertheless,  the  mTOR  pathway  regulates  amino  acid  biosynthesis,  glucose
homeostasis,  adipogenesis,  actin  cytoskeleton  polarization,  nutrient-response
transcription programs, ribosome biosynthesis,  size, growth, proliferation, aging,
survival, and life-span of every human cell[96,97].  As such, mTOR signalling is also
primarily  involved in  cancer  growth,  angiogenesis,  and metastasis  formation[96].
Outside the transplant setting, PSI have been successfully used for the treatment of
neuro-endocrine tumours[98] and advanced RCC[99]. Encouraging results have been also
obtained in KTx recipients with NMSC[100] and Kaposi’s sarcoma[101]. Currently, there
are no formal recommendations on how to manage immunosuppression in patients
with post-transplant malignancies but common trend is to reduce CNI and switch
from MPA to mTOR-I whenever possible[83]. Recent reports suggest that using mTOR-
I may be a valid option also in recipients with localised allograft RCC but larger
populations and long-term outcomes are needed to confirm this hypothesis[7,9,13,18].
Increased risk of rejection[102]  and severe drug-related side effects[103]  are the main
drawbacks  of  the  strategy  and  therefore  a  tailored  approach  based  on  specific
patient’s and cancer’s characteristics should be preferred.
FOLLOW-UP STRATEGIES
In  our  review,  we  found  minimal  information  regarding  follow-up  protocols.
Proposed  strategies  were  also  quite  heterogeneous  in  terms  of  timing  and
techniques[7,14,18].  Overall,  the risk of local recurrence and metastatic disease after
successful treatment of T1aN0M0 and T1bN0M0 RCC in native kidneys is extremely
low[32]. Albeit limited, experience in KTx suggests that cancer-specific outcomes are
not significantly different[7,14,18,34].  As such, it seems reasonably safe to adopt what
recommended by current AUA[32] or EAU guidelines[104]. Considering the risk and the
burden  of  CIN  in  KTx  recipients,  colour-Doppler  US,  CEUS  or  MRI  should  be
preferred over CT scan with contrast media[105].  After AT, discriminating between
necrosis,  inflammation,  neoplastic  tissue  and  normal  parenchyma  can  be
challenging[14]. In this context, protocol ablation-site biopsy may help promptly detect
persistent or recurrent neoplasms[106].
CONCLUSION
Kidney allograft RCC represents a difficult challenge for the transplant community.
Maximal renal function preservation is paramount to achieve the best outcome. In this
regards, post-transplant routine follow-up colour-Doppler US may help detect lesions
amenable of conservative treatment. Renal mass biopsy is advised for diagnostic
purpose and proper treatment planning. Ideally, RCC should be assessed using the
Fuhrman grading score and the modified AJCC staging system. Compared to the
general population, higher incidences of papillary type RCC have been demonstrated
among recipients with allograft neoplasms. Over years, improved surgical techniques
and technological advances have favoured the use of NSS and AT over graftectomy.
Available data on T1aN0M0 RCC are reassuring as they show excellent cancer-related
outcomes,  acceptable complication rates,  and optimal allograft  function whereas
experience with T1bN0M0 remains mostly anecdotal (Table 1). RCC type and growth
patter do not seem to affect primary treatment efficacy and relapse rates. Due to the
rarity  of  the  disease  and  the  lack  of  properly  designed  studies,  no  hard
recommendation can be made (Table 2). A reasonable approach would be to choose a
tailored strategy considering both patient’s and tumour’s characteristics. Individual
WJT https://www.wjgnet.com June 29, 2020 Volume 10 Issue 6
Motta G et al. Kidney allograft renal cell carcinoma
153
surgical  risk  and  local  expertise  are  also  important.  Multi-centre  prospective
comparative trials are warranted.
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Table 1  Summary of conservative treatments of localised allograft renal cell carcinoma1
RFA CA MWA HIFU IRE NSS
Ref. Charboneau et al[107] Shingleton et al[60] Gul et al[63] Chakera et al[77] Gul[63] Chambade et al[11]
Baughman et al[108] Cornelis et al[61] Favi et al[69] Di Candio et al[76] Varotti et al[39]
Roy et al[35] Ploussard et al[62] Tillou et al[42]
Goeman et al[109] Guleryuz et al[34] Barama et al[47]
Aron et al[106] Gul et al[63] Kaouk et al[41]
Matevossian et al[110] Mundel et al[122]
Veltri et al[111] Ribal et al[123]
Sanchez et al[112] Lamb et al[124]
Elkentaoui et al[113]
Olivani et al[114]
Cornelis et al[61]
Leveridge et al[115]
Tillou et al[18]
Swords et al[116]
Végső et al[117]
Su et al[118]
Christensen et al[119]
Hernández-Socorro et al[120]
Guleryuz et al[34]
Cool et al[121]
Iezzi et al[48]
Di Candio et al[76]
Patients (n) 70 11 5 3 1 61
Lesions (n) 78 11 5 3 1 63
FU (range) 3-71 mo 1-59 mo 8-61 mo 73-81 mo 34 mo 5-109 mo
RCC type
CC (n) 10 7 2 1 1 24
PA (n) 41 3 3 2 0 33
Other (n) 5 1 0 0 0 2
NA (n) 22 0 0 0 0 4
Size (range) 0.5-4.0 cm 1-4.1 cm 2.2-3.1 cm 0.8-5.5 cm 1.6 cm 0.9-7.0 cm
TNM2
T1aN0M0 (n) 78 10 5 2 1 60
T1bN0M0 (n) 0 1 0 1 0 3
PTF (n) 2 0 0 1 0 0
Relapse (n) 1 0 0 0 0 0
DSM (n) 0 0 0 0 0 0
1Summaries based on individual cases should not considered as an estimate of the “real world”.
2American Joint Committee on Cancer Tumour Node Metastasis Staging System. RFA: Radiofrequency ablation; CA: Cryoablation; MWA: Microwave
ablation; HIFU: High-intensity focused ultrasound; IRE: Irreversible electroporation; NSS: Nephron-sparing surgery; FU: Follow-up; RCC: Renal cell
carcinoma; CC: Clear cell; PA: Papillary; NA: Not available; TNM: Tumour node metastasis; PTF: Primary treatment failure; DSM: Disease-specific
mortality.
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Table 2  Advantages and limitations of conservative treatments of localised allograft renal cell carcinoma
Advantages Limitations
Nephron-sparing surgery Complete tumour removal Technically demanding
Definitive histology Invasive
Easy imaging-based follow-up Higher peri-operative complication rate
Good preliminary results with T1bN0M0 Higher risk of allograft dysfunction
Focal ablation Minimally invasive Higher risk of primary treatment failure
Highly selective Lack of definitive histology
Can treat centrally located lesions Difficult imaging-based follow-up
Lower peri-operative complication rate Dubious results with T1bN0M0
Better allograft function preservation
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